Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
Bristol Myers Squibb said on May 29 that it has filed for a label expansion of its CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in…
To read the full story
BUSINESS
- Kaken, Gilead Ink Japan Sales Partnership for Seladelpar
June 1, 2026
- Astellas Rebuts ISS Opposition to Outside Director Nominee
June 1, 2026
- BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
June 1, 2026
- Shionogi’s OIC Drug Naldemedine Bags Approval in China
June 1, 2026
- Eylea Bio-AG Snags 60% Share in Just 3 Months, Outpacing Biosimilar
May 29, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…